AWP
PCRX icon

Abacus Wealth Partners’s Pacira BioSciences PCRX Stock Holding History

Abacus Wealth Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,495
Closed -$220K – 547
2025
Q4 		$220K Buy
+8,495
New +$202K 0.02% 452

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Abacus Wealth Partners's PCRX Position: Q1 2026 in Review

Abacus Wealth Partners sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 8,495 shares — an estimated $220K sold.

Abacus Wealth Partners first reported a position in PCRX in Q4 2025 and held it in 1 quarter. The position peaked at $220K in Q4 2025. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Abacus Wealth Partners reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
  • Abacus Wealth Partners sold 8,495 Pacira BioSciences shares in Q1 2026, an estimated $220K.
  • Abacus Wealth Partners first reported a position in Pacira BioSciences in Q4 2025 and held it in 1 quarter.
  • Abacus Wealth Partners's Pacira BioSciences position peaked at $220K in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Abacus Wealth Partners's 13F filing for Q1 2026, filed 24 Apr 2026.